IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR, CSF-1R, CSF-1-R, MACROPHAGE COLONYSTIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)), HUMANIZED MONOCLONAL ANTIBODY
Fallopian Tube Undifferentiated Carcinoma
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 34/ 100
- Competitive Position
- 95/ 100
Competitive context
73 Active assets in the Fallopian Tube Undifferentiated Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Women's Hospital School Of Medicine Zhejiang University | Phase 3 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II Mayo Clinic | Phase 3 | BB |
TAMOXIFEN Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Phase 3 | BB |
Cyclophosphamide Mayo Clinic | Phase 2 | BB |
Pembrolizumab Roswell Park Cancer Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR, CSF-1R, CSF-1-R, MACROPHAGE COLONYSTIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)), HUMANIZED MONOCLONAL ANTIBODY is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →